secwatch.observer — SEC 8-K summary
======================================

Issuer:     Greenland Mines Ltd (GRML)
CIK:        0001907223
Form:       8-K
Filed at:   2025-06-30T23:59:59+00:00
Accession:  0001213900-25-059753
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Klotho Neurosciences begins manufacturing of ALS gene therapy KLTO-202, targeting Phase I/II start by Q3 2026
--------------------------------------------------------------------------------

- KLTO-202 gene therapy manufacturing underway; process development & manufacturing expected to take approx. 8 months.
- Company targets FDA meetings, animal safety studies, IND filing, and Phase I/II trial start by Q3 2026.
- Therapy uses s-KL RNA splice variant of alpha-Klotho gene licensed from Autonomous University of Barcelona.
- Animal studies in ALS, Alzheimer's, and aging models showed favorable therapeutic outcomes.
- Company will use CROs to manage manufacturing and clinical trials, avoiding large staff increases.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1907223/000121390025059753/0001213900-25-059753-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1907223/000121390025059753/ea0247557-8k_klotho.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-059753

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer